Ratings by Bernstein SocGen Group (Jeffrey Walch)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/25/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 8/25/2026 | Summit Therapeutics plc | SMMT | Upgrade | Market Perform (Underperform) |
13.16 (14.16) |
7.6% | Details | |
| 8/21/2026 | Revolution | RVMD | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/14/2026 | Regeneron Pharma | REGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/11/2026 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/24/2026 | Nuvalent | NUVL | Downgrade | Market Perform (Outperform) |
123.42 (123.96) |
0.44% | Details | |
| 6/22/2026 | Summit Therapeutics plc | SMMT | Maintain | Underperform (N/A) |
|
Details | ||
| 6/10/2026 | Nuvalent | NUVL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/9/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/5/2026 | BioNTech | BNTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/4/2026 | Nuvalent | NUVL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2026 | Summit Therapeutics plc | SMMT | Maintain | Underperform (N/A) |
|
Details | ||
| 5/26/2026 | Summit Therapeutics plc | SMMT | Maintain | Underperform (N/A) |
|
Details | ||
| 5/21/2026 | Incyte | INCY | New Coverage | Market Perform (N/A) |
97.08 (125.01) |
28.77% | Details | |
| 5/21/2026 | Revolution | RVMD | New Coverage | Market Perform (N/A) |
150.33 (209.87) |
39.61% | Details | |
| 5/21/2026 | Jazz Pharmaceuticals | JAZZ | New Coverage | Market Perform (N/A) |
239.01 (243.71) |
1.97% | Details | |
| 5/21/2026 | BioNTech | BNTX | New Coverage | Market Perform (N/A) |
90.36 (101.95) |
12.83% | Details | |
| 5/21/2026 | Summit Therapeutics plc | SMMT | New Coverage | Underperform (N/A) |
17.89 (13.16) |
-26.44% | Details | |
| 5/21/2026 | Neurocrine Bio. | NBIX | New Coverage | Outperform (N/A) |
154.67 (156.76) |
1.35% | Details | |
| 5/21/2026 | Nuvalent | NUVL | New Coverage | Outperform (N/A) |
102.32 (123.42) |
20.62% | Details |
